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Valproic acid and its derivatives are now commonly used to treat various psychiatric disorders in the elderly. Data indicates that
the elderly patients are more susceptible to developing neuropsychiatric complications when treated with these medications. In
this report, we describe the case of a 66-year-old woman with early-onset, Alzheimer’s type dementia, who developed myoclonus
when treated with a valproic acid preparation for behavioral disturbances associated with the dementia.
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1.Introduction
Developed originally as an anticonvulsant medication, the
use of valproic acid (VPA) in patients with psychiatric
disorders has increased in recent years [1]. Given the current
concerns regarding the use of the antipsychotic medications
in older patients with dementia, there is interest in using
mood stabilizing anticonvulsants for demented patients with
agitation and behavioral problems [2, 3]. We are reporting
the case of a woman with early-onset, Alzheimer’s type
dementia, who developed an adverse reaction to a valproic
acid preparation when used for treating behavioral problems
associated with the dementia. Although myoclonus in the
absence of ammonemia and normal valproic acid level has
been reported in a 42-year-old depressed patient treated
with VPA [4], from our review of literature, this is the ﬁrst
reported case of myoclonus due to valproic acid in a patient
with dementia when used to treat behavioral disturbances.
2.CaseReport
Ms.JB,a66-year-oldCaucasianwoman,wasadmittedtoour
inpatient geriatric psychiatry unit from her long term care
(LTC) facility because of behavioral disturbances associated
with her dementing illness. She was resistant to care,
was having persistent vocalization, and was hallucinating.
Functionally, she required full assistance with all her ADLs.
Her past medical history included early-onset dementia of
Alzheimer’s type, severe, hyperlipidemia, hypertension, and
dysphagia. The patient did not have a history of psychiatric
illness including anxiety, psychosis, substance abuse, or
psychiatric hospitalizations.
Hermedicationsatadmissiontoourunitweremultivita-
mins, citalopram 20mg po daily, simvastatin 40mg po daily,
Vitamin D3 1000IU po daily, calcium carbonate 600mg po
bid, valproic acid sprinkles 375mg po twice daily, docusate
100mg po twice daily, and risperidone 0.5mg po twice daily.
Our review of record, indicates that the patient was
being treated with citalopram, valproic acid sprinkles, and
risperidone for the behavioral disturbances associated with
her dementia. It is unclear exactly as to when the valproic
acid sprinkles was started, but it appears that the patient
was taking this drug for at least the last month prior to her
hospitalization.
On admission examination, the patient was noted to be
perseveratively calling out and crying. Her vital signs were
stable, and she was uncooperative to the examination. She
was underweight, at 66 inches in height, 99lbs in weight, and
body mass index (BMI) = 16kg/m2. Despite her history of
hypertension, her blood pressure (BP) on admission was low
at 96/57mmhg. She was noted to have a dysconjugate gaze.
She had marked jerking movements of her upper extremities2 Case Reports in Medicine
consistentwithmyoclonus.Muscletonewasincreased,andit
was diﬃcult to assess for cogwheeling, as patient was unable
to voluntarily relax her extremities. Myoclonus in her lower
extremities was also noted when her feet were dorsiﬂexed.
She was disoriented to time, place, and person and was
unable to participate in a formal cognitive testing.
Laboratory examination on admission revealed a low
serum albumin of 3.4gm/dL. Her ammonia level was low
normal at 4umol/L. Her valproic acid level was 39mg/L, a
level generally considered to be subtherapeutic for patients
with seizure disorders. Sodium was 143meq/L, potassium
was 3.7meq/L, chloride was 104meq/L, bicarbonate was
33meq/L, blood urea nitrogen (BUN) was 12mg/dL, serum
creatinine was 0.7mg/dL, glucose was 91mg/dL, serum
calcium was 8.5mg/dL, aspartate transamisase (AST) was
7iu/L, and alanine transaminase (ALT) was 21iu/L. Vita-
min B12, folate, and thyroid stimulating hormone (TSH)
levels were normal. Urinalysis was unremarkable. Complete
blood count (CBC) was normal with a white cell count
of 8100/cmm, a hemoglobin level of 13.7gm/dL, and a
hematocrit of 41.2%.
Following the initial evaluation, the VPA dose was
decreased and then discontinued, with complete resolution
of her myoclonus. Quetiapine was started and titrated to
25mg po at noon and 12.5mg po at 5pm for agitation.
Because of her late afternoon agitation, risperidone 0.5mg
was increased from twice a day to 0.5mg po three times a
day, with the additional dose given in the early afternoon.
Her restlessness, agitation, vocalizations, hallucinations and
resistance to care were signiﬁcantly decreased from admis-
sion on this medication regimen. She was discharged back to
her long term care facility in a stable state.
3. Discussion
VPA is itself a simple fatty acid and can disrupt the urea
cycle by causing impairment in the body’s usual fatty acid
metabolism [5]. The disruption in the urea cycle causes
high serum ammonia levels [5]. Encephalopathy secondary
to hyperammonemia caused by VPA has been reported
by others [6, 7] as well as encephalopathy and myoclonus
associated with VPA in the absence of a signiﬁcantly elevated
ammonia level [8]. Our patient’s ammonia level was low
normal, and her VPA level was not elevated. Her serum
liver enzyme levels were normal. However, discontinuation
of VPA was associated with a complete resolution of the
myoclonus. Therefore, a serum level of VPA which would
not normally be considered to be high appears to have been
responsible for her myoclonus. Because valproic acid is a
mitochondrial toxin, it can cause myoclonus even when it
does not cause high serum ammonia levels [5, 9].
We considered delirium as a diﬀerential diagnosis for the
patients behavioral disturbances that give her age and her
history of dementia [10]. To this end we also completed a
work up which was essentially normal. Although delirium
remained a possibility, the lack of ﬂuctuating levels of
consciousness and no evidence for metabolic or infectious
causes for her behavioral issues made this diagnosis less
likely.
The patient came to us with a history of hypertension,
but she was found to have several recordings of low blood
pressures during her stay at our unit. After a careful review,
we concluded that these blood pressure changes were due to
autonomic failure associated with her severe dementia and
the psychotropic medications that she was taking [11, 12].
Although she had her several blood pressure recordings that
werelowduring herhospitalization, shealsohadseveraldays
where her blood pressure recordings were normal. Her blood
pressures prior to discharge ranged 103–107/63–69mmhg.
It remains unclear from literature as to when an elderly
patientwillbesusceptibletothedevelopingneuropsychiatric
side-eﬀects from VPA. However, available data indicates that
all elderly patients treated with VPA should be closely mon-
itored regardless of the duration of therapy and especially
during periods of acute illness [13, 14]. For those patients
who develop myoclonus despite close monitoring, the VPA
should be discontinued immediately.
Elderly patients are very sensitive to side eﬀects of
medications [15]. In this patient, an anticonvulsant mood
stabilizer,VPA,wasgiveninanattempttoavoidthepotential
for the extrapyramidal and cerebrovascular side eﬀects of
antipsychotic drugs proﬁles. However, VPA was not eﬀective
in controlling her agitation and behavioral disturbances,
and it caused its own untoward side eﬀect of myoclonus.
Although some psychotropic medications have been found
to be helpful in the treatment of BPSD, none of them have
proveneﬃcacyandbenignside-eﬀectproﬁles[3,16].Elderly
patientsalsohavemoremedicalcomorbiditiesandaretaking
multiple medications [17]. This puts them at higher risk
for developing medical complications and medication side-
eﬀects along with drug-drug interactions proﬁles [15]. These
issues must be considered while giving a new medication to
the older patient especially with dementia.
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